AEON · AEON Biopharma, Inc.

Substantial doubt about the company's ability to continue as a going concern.

“As a result of these conditions, management has concluded that substantial doubt about our ability to continue as a going concern exists as conditions and events, considered in the aggregate, indicate that it is probable that we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this Report are issued.”